Survodutide
BI 456906 · Dual GLP-1/Glucagon Agonist
Boehringer Ingelheim's dual GLP-1/Glucagon agonist — targeting both appetite and metabolic rate for obesity and liver disease.
Educational content only. Not medical advice. This compound may be regulated in your jurisdiction. Consult a healthcare professional.
01 What is Survodutide?
Survodutide represents a different flavour of next-gen weight loss peptide. While Tirzepatide combines GLP-1 and GIP, Survodutide combines GLP-1 and glucagon — betting that the energy expenditure boost from glucagon activation is more valuable than the GIP component. Early data suggests this bet may be paying off, particularly for liver fat reduction. The GLP-1/glucagon combination is theoretically elegant: GLP-1 suppresses appetite and improves insulin sensitivity, while glucagon ramps up hepatic energy expenditure and fat oxidation. You eat less AND burn more — particularly visceral and hepatic fat. For people with NAFLD/NASH (fatty liver disease), this dual mechanism is especially attractive because glucagon directly drives liver fat clearance. Developed by Boehringer Ingelheim, Survodutide is in Phase 3 trials for obesity and NASH. Phase 2 results showed up to 19% weight loss at 46 weeks and dramatic liver fat reduction. It is not quite at Retatrutide's 24% level, but it may have advantages for metabolic liver disease specifically.
02 How Does It Work?
Survodutide activates two receptors: 1. GLP-1 receptor: Appetite suppression, improved glycaemic control, slowed gastric emptying, cardiovascular benefit. This component handles the 'eat less' side. 2. Glucagon receptor: Increases hepatic glucose output (offset by GLP-1's insulin effect), dramatically increases energy expenditure, promotes fatty acid oxidation in the liver, reduces hepatic steatosis. This handles the 'burn more' side. The ratio of GLP-1 to glucagon activity is carefully balanced — enough glucagon for metabolic benefit without causing hyperglycaemia (because GLP-1 counteracts glucagon's glucose-raising effects).
03 What Does The Research Say?
Moderate evidence. Some human data, mostly animal studies.
Phase 2 obesity trial (2024): Up to 19% weight loss at highest dose (4.8mg) over 46 weeks. Significant dose-response relationship. Liver fat reduction: up to 86% relative reduction in hepatic fat content. NASH trials: Phase 2 results show significant improvements in liver histology — fibrosis improvement in many participants. Phase 3 for NASH ongoing. Comparison: Weight loss slightly less than Retatrutide but liver fat reduction is standout. May become first-line for metabolic liver disease with obesity.
04 Reported Dosages
Research literature dosages only. NOT medical recommendations. Always consult a healthcare professional.
Clinical trial doses: Escalated from 0.3mg to 4.8mg weekly subcutaneous injection over several weeks. Maximum dose tested: 4.8mg weekly. Slow dose escalation essential for tolerability. DISCLAIMER: NOT APPROVED for clinical use. Phase 3 trials ongoing. Only available as research chemical outside trials. Quality and purity of non-pharmaceutical sources cannot be guaranteed.
05 Side Effects & Risks
Similar GI profile to other incretin-based therapies: nausea, vomiting, diarrhoea (dose-dependent, improves with time). Potentially more nausea than pure GLP-1 agonists due to glucagon component. Specific concerns: glucagon activation raises heart rate slightly (monitored in trials), potential for muscle loss (resistance training essential), gallbladder events with rapid weight loss. Appetite loss can be profound — need to maintain adequate protein intake.
06 Legal Status
Not approved. Research chemical only.
Not FDA-approved. Phase 3 trials ongoing (Boehringer Ingelheim).
Not EMA-approved. Clinical trials active.
Not TGA-approved. Research chemical.
Goal Guides for Survodutide
Explore how Survodutide may support specific health goals: